LMS1007 for COVID-19

LMS1007 has been reported as potentially beneficial for COVID-19 in the following study.

COVID-19 involves the interplay of 350+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 10,000+ potential treatments. c19early.org analyzes 210+ treatments. We have not reviewed LMS1007 in detail.

Study suggesting benefit with LMS1007

Saadah et al., Synthesis, molecular docking, and in vitro activity of a novel angiotensin-converting enzyme 2 inhibitor, LMS1007: a potential molecule in Covid-19 and cancer treatments, RSC Advances, doi:10.1039/d5ra01134e

Angiotensin-converting enzyme 2 (ACE2) is a validated common protein in the pathology of several diseases, including novel coronavirus and breast cancer.